Patients with pancreatic cancer show a dismal prognosis, with 5-year overall survival rates of 7%-8% in both Japan and the USA. 
matrix metalloproteinase (MMP), and secreted protein acidic and rich in cysteine (SPARC). 5 Under normal circumstances, the extracellular matrix conserves cellular polarity, proliferation, and migration while inhibiting dysplasia. 6 In contrast, dysregulated integrin subunits, seen in the basement membrane in pancreatic cancer tissue, contribute to cancer-cell survival and invasiveness. 7, 8 Hyaluronan, a glycosaminoglycan, is deposited in high concentration in the extracellular matrix of pancreatic cancer. 9 Once hyaluronan binds to its receptor, CD44, subsequent interactions prolong cancer-cell survival and promote cancer cell growth.
Stromal cells in pancreatic cancer comprise cancer-associated fibroblasts (CAFs), endothelial cells, and immune cells. Pancreatic stellate cells are a subset of CAFs. 10 CAFs are a major component of pancreatic cancer stroma, derived from different kinds of progenitor cells such as fibroblasts, pancreatic stellate cells, and epithelial, endothelial, and mesenchymal stem cells. 11, 12 CAFs express α-smooth muscle actin (α-SMA), a well-known and reliable marker of CAF, stromal cell-derived factor-1α, fibroblast activation protein, and fibroblast specific protein-1. 3, 11 CAFs are activated by transforming growth factor β (TGF-β), sonic hedgehog, tumor necrosis factor α (TNF-α), platelet-derived growth factor (PDGF), and interleukin (IL)-1, -6, and -10. 11,13 TGF-β regulates tumor growth, differentiation, and immune cell function.
14 TGF-β initially plays a tumor-suppressive role, but enhances tumor growth as cancer progresses. 6, 15 TGF-β1 enhances the ability of CAFs to form abundant filopodia, which allows CAFs to migrate into cancer cell nests. 13 CAFs are stimulated by several types of mediators such as C-C motif chemokine ligand 2 (CCL2), hepatocyte growth factor (HGF), and fibroblast growth factor (FGF).
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However, some growth factors including insulin-like growth factor (IGF), epidermal growth factor (EGF), and TGF-β are derived from CAFs. 6, 14 CAFs induce desmoplasia through the secretion of collagen types I and III, fibronectin, proteoglycans, and glycosaminoglycans, leading to increased mechanical pressure in the extracellular matrix, which may promote cancer-cell migration and inhibit vascularization. 3 CAFs provide cancer cells with nourishment under low-glucose conditions. 11 CAFs also contribute to epithelial-to-mesenchymal transition (EMT), cancer invasion, angiogenesis, and metastasis. Tregs are present. 6 Cytotoxic T-lymphocyte-associated protein 4
(CTLA-4), which is constantly expressed on Tregs, plays a central role in suppressing antigen-presenting cells. MDSCs induce immune evasion by inhibiting both innate and adaptive antitumor immunity in pancreatic cancer. 21 Pancreatic-cancer patients with higher levels of circulating MDSCs correlated with poorer overall survival. 31 TAMs are macrophages that comprise a major com- 34 Peranzoni et al 35 reported that macrophages inhibit CD8 + tumor-infiltrating lymphocytes (TIL).
| Tumor-infiltrating immune cells in pancreatic cancer
Cancer cells are surveyed by the host immune system, which eliminates cancer in the first phase. Cancer and immunity are then balanced in the next phase. In the last immune-evasion phase, cancer appears in the human body. This theory of immunoediting was developed only recently. 36 TILs are considered to reflect immunoediting. 37 51 Moreover, proteomic analysis of pancreatic cancer treated with NACRT showed that marginal-zone B-and B1-cell-specific protein (MZB1) expression was associated with abundant CD8 + TIL and longer survival. 52 These results indicate that immunogenic cell death induced by chemoradiation plays a pivotal role in pancreatic cancer.
| Immunomodulation induced by drugs or X-ray in pancreatic cancer
gemcitabine plus S-1 followed by 30 Gy radiation for pancreatic cancer enhances both CD4 + and CD8 + TILs. Furthermore, abun
| C AN CER S TROMA-TARG E TING THER APY FOR PAN CRE ATI C C AN CER
Depletion of the desmoplastic stroma has led to better chemotherapy delivery and drug response in preclinical models of pancreatic cancer. [53] [54] [55] Antifibrotic therapy therefore appears to represent a promising strategy in the treatment of pancreatic cancer. The first successful approach to reduce CAF proliferation that led to depletion of tumor stroma and better gemcitabine delivery and prolonging survival in initial preclinical studies, was achieved through inhibition of sonic hedgehog signaling. 54 The results of that study paved the way for clinical trials. Various
hedgehog-pathway inhibitors were tested in a phase II trial in the setting of advanced solid tumors, including pancreatic cancer.
Unfortunately, this very promising approach in targeting the proliferation of CAFs using hedgehog-pathway inhibitors failed in phase II trials. 70 Other preclinical studies indicated that sonic hedgehog signaling inhibition resulted in tumor progression even though desmoplasia was decreased. 71, 72 Moreover, clinical research using pancreatic cancer patient specimens demonstrated that high stromal density was associated with longer survival. 73 Given these results, part of the components of desmoplastic stroma work as tumor-restraining rather than as tumor-promoting. 74 A similar lesson has been learned from multi-MMP inhibitors, which did not improve survival among patients with PDAC in clinical trials, despite encouraging preclinical data. Recent data, however, have
shown that some MMPs are protective against cancer and others are not, so non-selective inhibition also cancels the protective effects of some MMPs. Furthermore, initial clinical trials were faulty in that inhibitors were tested in late-stage cancers, whereas animal data were obtained during cancer initiation. Timing has to be taken into consideration, and entry criteria for clinical trials should be early-stage of cancer patients in order to match animal data. 60 In a mouse model, a TGF-β antagonist suppressed metastasis without any adverse effects. 75 In another report, TGF-β inhibition reduced pancreatic cancer stroma in an orthotopic pancreaticcancer mouse model, suggesting TGF-β inhibition as a potential treatment for controlling stroma density. 62 In a phase Ib clinical trial, the TGF-β inhibitor galunisertib was given in combination with gemcitabine to patients with advanced or metastatic pancreatic cancer. 76 The response rate with TGF-β inhibition therapy was 42.9% with acceptable safety. Chimeric antigen receptor T-cell (CAR-T) therapy has shown high remission rate for patients with acute lymphoblastic leukemia. 90 Cultured T cells transferred with the CAR gene using a retroviral or lentiviral vector are reinjected into the host. CAR-T therapy directly stimulates cell-mediated immunity, and can thus induce stronger antitumor immune reaction than antibody therapy. 91 Several studies of CAR-T therapy for pancreatic cancer are under way. 88 Targeting immunosuppressive cells may be promising. Tumorinfiltrating Tregs in melanoma patients highly express chemokine receptor type 4 (CCR4), a potential target for Treg depletion.
| IMMUNOTHER APY FOR PAN CRE ATIC C AN CER
CCR4 antibody has been shown to remove effector-type Treg both in vivo and in vitro. 92 Mogamulizumab, a humanized anti-CCR4 antibody therapy for solid tumors, is under clinical study. 93 Bacterial therapy may become a potential immunotherapy for pancreatic cancer. Salmonella typhimurium A1-R has been shown to be effective in patient-derived xenograft mouse models of pancreatic cancer. 94 In addition, S. typhimurium A1-R enhanced CD8 + TILs in a syngeneic pancreatic cancer mouse model, suggesting activation of host antitumor immunity. 95 
| CON CLUS IONS
The tumor microenvironment in pancreatic cancer contributes to tumor growth, invasion, and metastasis in a multifaceted way, including immune evasion. New immunotherapies or cancer stromatargeting therapies have potential to induce a cure for pancreatic cancer.
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